Impact of Frailty and Other Co-Morbidities of Lung Cancer Outcomes
Advances in medical oncology, radiation oncology and thoracic surgery have made advanced treatments available to older and more frail patients. A better understanding the interaction of patient frailty and comorbidities to evolving interventions and outcomes is needed.
This session will involve three lectures given by a thoracic surgeon, medical oncologist and radiation oncologist to explore individual patient variables that may influence complications related to treatment. Some of these variables may be well understood (such as poor lung function, renal failure) and some may be less well defined and less well understood, such as patient frailty, exercise capacity or body muscle mass.
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pulmonologists.
Upon completion of this activity, participants should be able to do the following:
- Better assess important variables in determining risk of lung resection for lung cancer.
- Better understand determinants of complications in radiation treatments for lung cancer.
- Better understand determinants of complications following treatment with chemotherapy, targeted therapy and immunotherapy for lung cancer.
- Philip Linden, MD
- Sue Yom, MD, PhD, FASTRO
- Leonidas Tapias, MD
- Mehmet Altan, MD, MD
- Pranshu Mohindra, MD
A list of all meeting faculty and Individual presenter disclosures are linked to their names in the Schedule of Events.
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee website page.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 0.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.75 Certificate of AttendanceThis activity was designated for 0.75 AMA PRA Category 1 Credit™.